Skip to content

Autologous Platelet rich plasma versus autologous growth factor concentrate & normal saline dressing in chronic non-healing wounds

Prospective Randomised Controlled Trial:Autologous Platelet rich plasma versus autologous growth factor concentrate & normal saline dressing in chronic non-healing wounds - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110599
Enrollment
150
Registered
2026-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Prospective Randomised Controlled Trial:Autologous Platelet rich plasma, autologous growth factor concentrate in chronic non-healing wounds: PRP, CGF, Normal saline dressing in chronic

Sponsors

ACS Medical Research InstituteAMRI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between eighteen and seventy five years Patients with chronic non healing wound of more than four weeks Of duration Aetiology includes diabetic foot ulcer Venous ulcer Pressure ulcer Post traumatic chronic wound Hemodynamically stable patients Platelet count normal Hemoglobin normal Patient willing to provide written informed consent

Exclusion criteria

Exclusion criteria: Malignant ulcers Osteomyelitis underlying the wound Active gangrene requiring amputation Acute infected wounds requiring emergency debridement Severe anaemia Thrombocytopenia Autoimmune disease Coagulopathy Patients on anticoagulants and anti platelets Uncontrolled diabetes Immunocompromised patients Severe peripheral arterial diseases Pregnantand lactating women Patients unwilling for follow up Patient with systemic sepsis

Design outcomes

Primary

MeasureTime frame
Meaning reduction in BWAT score from baseline to 4 weeksTimepoint: At baseline,1st week,2nd week,3rd week, 4th weeks

Secondary

MeasureTime frame
Percentage reduction in wound are a Time to complete epithelization Reduction in VAS pain score Complication rateTimepoint: At baseline,1st week,2nd week,3rd week,4th week.

Countries

India

Contacts

Public ContactSowmiyaa N

Sri Lalithambigai Medical college and hospital

jeganath97@gmail.com9600754244

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026